Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type

Alzheimer Disease and Associated Disorders

Volumn 26, Issue 4, 2012, Pages 314-321

  Wang, Lei ^a   Fagan, Anne M ^b   Shah, Aarti R ^b   Beg, Mirza Faisal ^c   Csernansky, John G ^a   Morris, John C ^b   Holtzman, David M ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

amyloid; biomarkers; hippocampal subfields; magnetic resonance imaging (MRI); p tau; tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN DEGENERATION; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DENTATE GYRUS; FEMALE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA2 REGION; HIPPOCAMPAL DEGENERATION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SUBICULUM;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NERVE DEGENERATION; TAU PROTEINS;

EID: 84870239257     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e31823c0cf4     Document Type: Article

References (49)

1. Arnold SE, Hyman BT, Flory J, et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex. 1991;1:103-116.
2. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999; 45:358-368.
3. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx. 2004;1:213-225.
4. Chou YY, Lepore N, Avedissian C, et al. Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage. 2009;46:394-410.
5. de Leon MJ, DeSanti S, Zinkowski R, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2006;27:394-401.
6. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512-519.
7. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med. 2009;1: 371-380.
8. Spires-Jones TL, Stoothoff WH, de Calignon A, et al. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 2009;32:150-159.
9. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314:777-781.
10. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176-183.
11. Fagan AM, Roe CM, Xiong C, et al. Cerebrospinal fluid tau/beta-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343-349.
12. Li G, Sokal I, Quinn JF, et al. CSF tau/A(beta)42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631-639.
13. Csernansky JG, Wang L, Joshi S, et al. Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type. Neurology. 2000;55:1636-1643.
14. Wang L, Swank JS, Glick IE, et al. Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging. Neuroimage. 2003;20: 667-682.
15. Wang L, Miller JP, Gado MH, et al. Abnormalities of hippocampal surface structure in very mild dementia of the Alzheimer type. Neuroimage. 2006;30:52-60.
16. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
18. Andersson C, Blennow K, Almkvist O, et al. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging. 2008;29:1466-1473.
19. Stomrud E, Hansson O, Zetterberg H, et al. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol. 2010;67:217-223.
20. Buchhave P, Blennow K, Zetterberg H, et al. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One. 2009;4:e6294.
21. Sluimer JD, Bouwman FH, Vrenken H, et al. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging. 2010;31:758-764.
22. Vemuri P, Wiste HJ, Weigand SD, et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 2010;75:143-151.
23. Wahlund LO, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett. 2003;339:99-102.
24. Cirrito JR, May PC, O'Dell MA, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaqueassociated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844-8853.
25. Buckner RL, Head D, Parker J, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004; 23:724-738.
26. Csernansky JG, Wang L, Swank J, et al. Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage. 2005;25:783-792.
27. Wang L, Khan A, Csernansky JG, et al. Fully-automated, multi-stage hippocampus mapping in very mild Alzheimer disease. Hippocampus. 2009;19:541-548.
28. Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31: 968-980.
29. Beg MF, Miller MI, Trouve A, et al. Computing large deformation metric mappings via geodesic flows of diffeomorphisms. Int J Comp Vision. 2005;61:139.
30. SAS Institute Inc. SAS System for Windows, V913 (computer program) Version. Cary, NC: SAS Institute Inc.; 2004.
31. Fotenos AF, Snyder AZ, Girton LE, et al. Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology. 2005;64:1032-1039.
32. Jack CR Jr., Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000;55:484-489.
33. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci. 2010;30:2088-2101.
34. Schuff N, Woerner N, Boreta L, et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain. 2009;132(Pt 4):1067-1077.
35. Hampel H, Burger K, Pruessner JC, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 2005;62:770-773.
36. Leow AD, Yanovsky I, Parikshak N, et al. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage. 2009;45:645-655.
37. Apostolova LG, Dutton RA, Dinov ID, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol. 2006;63: 693-699.
38. Jarrett JT, Berger EP, Lansbury PT. The C-terminus of the beta protein is critical in amyloidogenesis. Ann NY Acad Sci. 1993;695:144-148.
39. Yin YI, Bassit B, Zhu L, et al. (Gamma)-secretase substrate concentration modulates the Abeta42/Abeta40 ratio: implications for Alzheimer disease. J Biol Chem. 2007;282: 23639-23644.
40. Becker JT, Davis SW, Hayashi KM, et al. Three-dimensional patterns of hippocampal atrophy in mild cognitive impairment. Arch Neurol. 2006;63:97-101.
41. Frisoni GB, Ganzola R, Canu E, et al. Mapping local hippocampal changes in Alzheimer's disease and normal ageing with MRI at 3 Tesla. Brain. 2008;131(Pt 12):3266-3276.
42. Scher AI, Xu Y, Korf ES, et al. Hippocampal shape analysis in Alzheimer's disease: a population-based study. Neuroimage. 2007;36:8-18.
43. Xie J, Alcantara D, Amenta N, et al. Spatially localized hippocampal shape analysis in late-life cognitive decline. Hippocampus. 2009;19:526-532.
44. Bobinski M, de Leon MJ, Tarnawski M, et al. Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Brain Res. 1998;805:267-269.
45. Bobinski M, Wegiel J, Wisniewski HM, et al. Neurofibrillary pathology-correlation with hippocampal formation atrophy in Alzheimer disease. Neurobiol Aging. 1996;17:909-919.
46. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397-405.
47. Driscoll I, Zhou Y, An Y, et al. Lack of Association Between 11C-PiB and Longitudinal Brain Atrophy in Non-demented Older Individuals Neurobiol Aging. 2010;32:2123-2130.
48. Hua X, Hibar DP, Lee S, et al. Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging. 2010;31:1463-1480.
49. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. Brain atrophy in healthy aging is related to CSF levels of A(beta)1-42. Cereb Cortex. 2010. bhp279.